ClinicalTrials.Veeva

Menu
S

Sun Valley Research Center, Inc | Imperial, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rapastinel
SPD489
Simufilam
Levomilnacipran
Lasmiditan
TNX-102
Lisdexamfetamine dimesylate
Cariprazine
SEP-4199
ABBV-932

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 59 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in pat...

Begins enrollment this month
Depression in Adults
Depression Disorders
Drug: CYB003
Behavioral: Psychological Support

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Active, not recruiting
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting
Attention Deficit/Hyperactivity Disorder
Drug: Centanafadine Hydrochloride

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling
Attention-Deficit/Hyperactivity Disorder
Drug: Placebo
Drug: 100mg SPN-812

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)
New

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Enrolling
Alzheimers Disease
Other: No Intervention

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how saf...

Enrolling
Bipolar II Disorder
Bipolar I Disorder
Drug: Placebo for ABBV-932
Drug: ABBV-932
Locations recently updated

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing,...

Enrolling
Migraine
Drug: Ubrogepant
Drug: Placebo for Ubrogepant

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately t...

Enrolling
Generalized Anxiety Disorder (GAD)
Drug: Antidepressant Therapy (ADT)
Drug: ABBV-932

Trial sponsors

AbbVie logo
Pfizer logo
Shire logo
Allergan logo
Allergan logo
Lilly logo
C
Sumitomo Pharma logo
Biohaven logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems